+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis B - Pipeline Review, H2 2019

  • ID: 4894198
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 476 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Abhelix LLC
  • Biological E Ltd
  • Dynavax Technologies Corp
  • Humabs BioMed SA
  • PharmaEssentia Corp
  • Theravectys SA
  • MORE
Hepatitis B - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H2 2019, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 24, 33, 1, 4, 75, 36 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 11 and 5 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abhelix LLC
  • Biological E Ltd
  • Dynavax Technologies Corp
  • Humabs BioMed SA
  • PharmaEssentia Corp
  • Theravectys SA
  • MORE
Introduction
Hepatitis B - Overview
Hepatitis B - Therapeutics Development
Hepatitis B - Therapeutics Assessment
Hepatitis B - Companies Involved in Therapeutics Development
Hepatitis B - Drug Profiles
Hepatitis B - Dormant Projects
Hepatitis B - Discontinued Products
Hepatitis B - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Hepatitis B, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Hepatitis B - Pipeline by Abhelix LLC, H2 2019
Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H2 2019
Hepatitis B - Pipeline by AIMM Therapeutics BV, H2 2019
Hepatitis B - Pipeline by Akshaya Bio Inc, H2 2019
Hepatitis B - Pipeline by Aligos Therapeutics Inc, H2 2019
Hepatitis B - Pipeline by AlphaMab Co Ltd, H2 2019
Hepatitis B - Pipeline by Altimmune Inc, H2 2019
Hepatitis B - Pipeline by Antios Therapeutics Inc, H2 2019
Hepatitis B - Pipeline by Arbutus Biopharma Corp, H2 2019
Hepatitis B - Pipeline by Arcturus Therapeutics Ltd, H2 2019
Hepatitis B - Pipeline by Ark Biosciences Inc, H2 2019
Hepatitis B - Pipeline by Ascentage Pharma Group International, H2 2019
Hepatitis B - Pipeline by Ascletis Inc, H2 2019
Hepatitis B - Dormant Projects, H2 2019
Hepatitis B - Discontinued Products, H2 2019
Hepatitis B - Discontinued Products, H2 2019 (Contd..1), H2 2019

List of Figures
Number of Products under Development for Hepatitis B, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Abhelix LLC
  • AiCuris GmbH & Co KG
  • AIMM Therapeutics BV
  • Akshaya Bio Inc
  • Aligos Therapeutics Inc
  • AlphaMab Co Ltd
  • Altimmune Inc
  • Antios Therapeutics Inc
  • Arbutus Biopharma Corp
  • Arcturus Therapeutics Ltd
  • Ark Biosciences Inc
  • Ascentage Pharma Group International
  • Ascletis Inc
  • Assembly Biosciences Inc
  • Aucta Pharmaceuticals LLC
  • Avalia Immunotherapies Ltd
  • Beijing Kawin Technology Share-Holding Co Ltd
  • Benitec Biopharma Ltd
  • Biological E Ltd
  • Biomics Biopharma Ltd
  • BioNet- Asia Co Ltd
  • Biotron Ltd
  • Bolder Biotechnology Inc
  • Brandenburg Antiinfektiva GmbH
  • Brickell Biotech Inc
  • BrightGene Bio-Medical Technology Co Ltd
  • Bukwang Pharm Co Ltd
  • Cadila Healthcare Ltd
  • CaPtivate Pharmaceuticals LLC
  • CaroGen Corp
  • Casterbridge Pharmaceuticals Inc
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd.
  • Chong Kun Dang Pharmaceutical Corp
  • Chongqing Zhifei Biological Products Co Ltd
  • Chromis Therapeutics Inc
  • Cinkate Corp
  • CN Bio Innovations Ltd
  • Cocrystal Pharma Inc
  • Collaborations Pharmaceuticals Inc
  • CyTuVax BV
  • DelSiTech Ltd
  • Dicerna Pharmaceuticals Inc
  • Dong-A Socio Holdings Co Ltd
  • Dynavax Technologies Corp
  • Elixiron Immunotherapeutics Inc
  • Enanta Pharmaceuticals Inc
  • Enyo Pharma SA
  • Etna Biotech Srl
  • Excision BioTherapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • FortuneRock (China) Ltd
  • Fujian Cosunter Pharmaceutical Co Ltd
  • G-Tech Bio LLC
  • GC Pharma
  • GemVax & KAEL Co Ltd
  • GeneCure LLC
  • GeneScience Pharmaceuticals Co Ltd
  • GeoVax Labs Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Golden Biotechnology Corp
  • Guangxi Hebabiz Pharmaceutical Co Ltd
  • Guangzhou Yipinhong Pharmaceutical Co Ltd
  • HEC Pharm Co Ltd
  • Hepion Pharmaceuticals
  • Huahui Anjian (Beijing) Biotechnology Co Ltd
  • Humabs BioMed SA
  • Huons Co Ltd
  • ImmuneMed Inc
  • Immunotope Inc
  • Innovent Biologics Inc
  • Inovio Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • ISR Immune System Regulation Holding AB
  • Jiangsu Alphamab Biopharmaceuticals Co Ltd
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Johnson & Johnson
  • Kainos Medicine Inc
  • KinoPharma Inc
  • LG Chem Ltd
  • Lion TCR Pte Ltd
  • Microbiotix Inc
  • MultiCell Technologies Inc
  • MYR GmbH
  • Novo Medi Sciences Pvt Ltd
  • Nucorion Pharmaceuticals Inc
  • Oncolys BioPharma Inc
  • Palisades Therapeutics
  • PharmaEssentia Corp
  • Precision Biosciences Inc
  • Profarma
  • Profectus BioSciences Inc
  • Qilu Pharmaceutical Co Ltd
  • Regeneron Pharmaceuticals Inc
  • Regulus Therapeutics Inc
  • Replicor Inc
  • Rodos BioTarget GmbH
  • Romark Laboratories LC
  • Samjin Pharm Co Ltd
  • Sclnow Biotechnology Co Ltd
  • Scynexis Inc
  • SFA Therapeutics LLC
  • Shanghai Henlius Biotech Inc
  • Shantha Biotechnics Pvt Ltd
  • Shenzhen BinDeBio Ltd
  • Sinovac Biotech Ltd
  • SL VaxiGen Inc
  • Spring Bank Pharmaceuticals Inc
  • Staidson BioPharma Inc
  • Suzhou Ribo Life Sciences Co Ltd
  • TaiGen Biotechnology Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • TCM Biotech International Corp
  • Tetranov International Inc
  • Theravectys SA
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • UBI Pharma Inc
  • Vaccitech Ltd
  • Vaxart Inc
  • Vaxine Pty Ltd
  • VBI Vaccines Inc
  • VenatoRx Pharmaceuticals Inc
  • Vir Biotechnology Inc
  • Viravaxx AG
  • Viriom Inc
  • Virion Therapeutics LLC
  • Virocovax
  • ViroStatics SRL
  • VLP Biotech Inc
  • Yisheng Biopharma Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll